All In Biotech

Drug Trial Radar · NCT00026312

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,449 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,449

Actual

Start

Oct 26, 2001

Primary completion

Jan 12, 2012

Study completion Dec 31, 2025

Sponsor

Sponsor type
NIH
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.

Conditions

  • Localized Resectable Neuroblastoma
  • Localized Unresectable Neuroblastoma
  • Recurrent Neuroblastoma
  • Regional Neuroblastoma
  • Stage 4 Neuroblastoma
  • Stage 4S Neuroblastoma

Interventions

  • AldesleukinBiological

    Given IV

  • DinutuximabBiological

    Given IV

  • IsotretinoinDrug

    Given PO

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Pharmacological StudyOther

    Correlative studies

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • SargramostimBiological

    Given IV or SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-Free Survival (EFS)Time frame: Three years

Locations

197 sites in 5 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Kaiser Permanente Downey Medical Center

    Downey, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Valley Children's Hospital

    Madera, California

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Rady Children's Hospital - San Diego

    San Diego, California

  • UCSF Medical Center-Parnassus

    San Francisco, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center

    Denver, Colorado

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Yale University

    New Haven, Connecticut

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Broward Health Medical Center

    Fort Lauderdale, Florida

  • Lee Memorial Health System

    Fort Myers, Florida

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida

  • Nicklaus Children's Hospital

    Miami, Florida

  • Miami Cancer Institute

    Miami, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Arnold Palmer Hospital for Children

    Orlando, Florida

Showing 40 of 197 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.